Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ADCT
ADCT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ADCT News
ADC Therapeutics Completes Enrollment for ZYNLONTA Clinical Trial
6d ago
PRnewswire
ADC Therapeutics Completes Enrollment for ZYNLONTA Clinical Trial
6d ago
Newsfilter
Biotech Sector Update: FDA and EU Approvals
Jun 26 2026
NASDAQ.COM
ADC Therapeutics Initiates Strategic Reorganization and Workforce Reduction
Jun 25 2026
NASDAQ.COM
ADC Therapeutics Cuts 17% Workforce to Focus on ZYNLONTA
Jun 24 2026
stocktwits
ADC Therapeutics Plans 17% Workforce Reduction to Enhance Financial Flexibility
Jun 24 2026
PRnewswire
ADC Therapeutics Announces 17% Workforce Reduction to Enhance Financial Flexibility
Jun 24 2026
Newsfilter
Pomerantz LLP Investigates ADC Therapeutics for Securities Fraud
Jun 23 2026
Globenewswire
Tango Therapeutics Appoints New Board Member
Jun 23 2026
NASDAQ.COM
Pomerantz LLP Investigates ADC Therapeutics for Securities Fraud
Jun 16 2026
Globenewswire
Pomerantz LLP Investigates ADC Therapeutics for Securities Fraud
Jun 09 2026
Globenewswire
ADC Therapeutics Plummets Over 50% on Phase 3 Trial Data
Jun 04 2026
seekingalpha
ADC Therapeutics Reports LOTIS-5 Trial Results for ZYNLONTA
Jun 03 2026
PRnewswire
ADC Therapeutics Q1 2026 Earnings Call Insights
May 04 2026
seekingalpha
ADC Therapeutics Q1 Financial Results Analysis
May 04 2026
seekingalpha
ADC Therapeutics Reports Q1 2026 Financial Results and Upcoming Milestones
May 04 2026
PRnewswire
Show More News
